rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DRUG
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky
      Nov 9MorningstarDRUG
      Weekly Roundup on the Cannabis Sector & Psychedelic Sector

      Key Takeaways; Cannabis Sector Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Creating Global Cannabis Powerhouse Canopy Growth Posted 22% Revenue Growth as International Cannabis Sales Surged 141% Key Takeaways; Psychedelic Sector Bright Minds Biosciences Received Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Trial Optimi Health Established Australian Subsidiary to Expand Psychedelic […]

      Nov 8Yahoo FinanceACBCGCDRUG
      Bright Minds Biosciences Stock: Promising Catalysts Despite The FDA Setback (NASDAQ:DRUG)

      Bright Minds Biosciences’ further studies or protocol changes could become a path past the FDA’s recent hold decision. Read more on DRUG stock here.

      Nov 5Seeking AlphaDRUG
      Bright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWS
      Nov 3Seeking AlphaDRUG
      FDA puts partial hold on Bright Minds’ Phase II seizure study
      Nov 3Yahoo FinanceDRUG
      Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
      Nov 2MorningstarDRUG
      Jefferies cuts Bright Minds stock price target on trial delays
      Nov 2Investing.comDRUG
      Baird cuts Bright Minds stock price target on clinical hold delay
      Nov 2Investing.comDRUG
      Bright Minds Biosciences Faces Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Study
      Nov 2Yahoo FinanceDRUG
      Why is Bright Minds Biosciences stock collapsing today?
      Nov 2Investing.comDRUG
      FDA Setback Clouds Timeline For Bright Minds Biosciences' Pediatric Epilepsy Trials
      Nov 2BenzingaDRUG
      Bright Minds stock plunges as FDA halts epilepsy trial
      Nov 2Investing.comDRUG
      Bright Minds Biosciences And 2 More Canadian Biotech Stocks
      Oct 8Yahoo FinanceDRUG
      Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

      NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P

      Sep 30Yahoo FinanceDRUG
      Bright Minds Biosciences (DRUG) Receives a Rating Update from a Top Analyst

      Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailDRUG
      Bright Minds Biosciences to Present at Upcoming Conferences

      NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:Cantor Global Healthcare Conference 2026 DATE:Wednesday, September 9,

      Sep 4Yahoo FinanceDRUG
      What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

      Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Aug 27Yahoo FinanceDRUG
      Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

      The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Aug 26Yahoo FinanceASMBDRUG

      This is the newest page. Registered accounts read further back.